ALK and lymphoma: Another study showed that PDGFR inhibition was a rational and effective therapeutic agent for nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) fusion lymphomas, suggesting that ALK might be a target of activating mutations of the genes encoding PDGFRA [20].